Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept.

Saved in:
Bibliographic Details
Title: Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept.
Authors: Aminu M; Departments of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Daver N; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Godoy MCB; Departments of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Shroff G; Departments of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu C; Departments of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Torre-Sada LF; Departments of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Goizueta A; Departments of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Shannon VR; Departments of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Faiz SA; Departments of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Altan M; Departments of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Garcia-Manero G; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kantarjian H; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ravandi-Kashani F; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kadia T; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Konopleva M; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., DiNardo C; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pierce S; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Naing A; Departments of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kim ST; Departments of Rheumatology and Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Kontoyiannis DP; Departments of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Khawaja F; Departments of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chung C; Departments of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu J; Departments of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sheshadri A; Departments of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Sep 29; Vol. 14, pp. 1249511. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1249511